163 related articles for article (PubMed ID: 32766136)
1. Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus.
Sciammarella C; Luce A; Riccardi F; Mocerino C; Modica R; Berretta M; Misso G; Cossu AM; Colao A; Vitale G; Necas A; Fedacko J; Galdiero M; Correale P; Faggiano A; Caraglia M; Capasso A; Grimaldi A
Front Oncol; 2020; 10():1047. PubMed ID: 32766136
[TBL] [Abstract][Full Text] [Related]
2. Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells.
von Hessert-Vaudoncourt C; Lelek S; Geisler C; Hartung T; Bröker V; Briest F; Mochmann L; Jost-Brinkmann F; Sedding D; Benecke J; Freitag H; Wolfshöfer S; Lammert H; Nölting S; Hummel M; Schrader J; Grabowski P
Front Pharmacol; 2024; 15():1308686. PubMed ID: 38375032
[No Abstract] [Full Text] [Related]
3. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
4. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Saif MW
Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
[TBL] [Abstract][Full Text] [Related]
5. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
Krug S; Mordhorst JP; Moser F; Theuerkorn K; Ruffert C; Egidi M; Rinke A; Gress TM; Michl P
PLoS One; 2019; 14(6):e0218953. PubMed ID: 31237925
[TBL] [Abstract][Full Text] [Related]
6. Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors.
Fotouhi O; Kjellin H; Larsson C; Hashemi J; Barriuso J; Juhlin CC; Lu M; Höög A; Pastrián LG; Lamarca A; Soto VH; Zedenius J; Mendiola M; Lehtiö J; Kjellman M
J Clin Endocrinol Metab; 2016 Oct; 101(10):3616-3627. PubMed ID: 27459532
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
[TBL] [Abstract][Full Text] [Related]
8. Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment.
Vitali E; Boemi I; Tarantola G; Piccini S; Zerbi A; Veronesi G; Baldelli R; Mazziotti G; Smiroldo V; Lavezzi E; Spada A; Mantovani G; Lania AG
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32748870
[TBL] [Abstract][Full Text] [Related]
9. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
[TBL] [Abstract][Full Text] [Related]
12. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
13. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
Ryan P; Phan AT; Adelman DT; Iwasaki M
Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
[TBL] [Abstract][Full Text] [Related]
15. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
16. Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.
Pusceddu S; Prinzi N; Lo Russo G; Femia D; Milione M; Perrone F; Tamborini E; Concas L; Pulice I; Vernieri C; Corti F; Buzzoni R; de Braud F
Future Oncol; 2017 Aug; 13(19):1677-1683. PubMed ID: 28580793
[TBL] [Abstract][Full Text] [Related]
17. [Antiproliferative Effect of Somatostatin Analogs - Data Analyses and Clinical Applications in the Context of the CLARINET Study].
Bencsiková B
Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
[TBL] [Abstract][Full Text] [Related]
18. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
20. Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors.
Beyens M; Vandamme T; Peeters M; Van Camp G; Op de Beeck K
Endocr Relat Cancer; 2019 Mar; 26(3):R109-R130. PubMed ID: 32022503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
